Ireland is reviewing how patients can access and purchase medical cannabis

Medical cannabis in Ireland is not a shop product. It is a clinical purchase: Schedule 2 products through the Medical Cannabis Access Programme, which has operated since 2021, and Schedule 1 products on a ministerial licence. That is a narrow, lawful channel — consultant-led, not recreational — and it is the only honest way to talk about “buying medical weed” on this island.

On 1 April 2026 the Minister for Health, Jennifer Carroll MacNeill, appointed Professor Shane Allwright to chair a Review of Access to Cannabis for Medical Use. The group is to report within twelve months of its first meeting. The brief is practical: how MCAP is working, whether more conditions should be included where the evidence supports it, how ministerial licences operate, and what a national policy on those licensed products should look like.

Why this is a positive movement story

A review is not a legalisation. It is the state taking the medical purchase path seriously: products, conditions, licences, and how patients actually get them. That is the same distinction we draw in our FAQs. Industrial hemp moves as a crop. Medical cannabis moves as a medicine. Mixing the two is how deals fail.

For Rehemption, based in Ireland, this is the medical side of the corridor. If policy widens the set of products or conditions that can be lawfully supplied, the farms and manufacturers that already meet medicines standards will need buyers, contracts, and import files that match HPRA and EU pharmaceutical rules — not a hemp fibre invoice with a different label. We will follow the review as it lands, and we will keep medical cannabis on the medicines path.